Pfizer Berobenatide Phase 2b Monthly Dosing

Key Takeaways

• VESPER-3 met its primary week-28 weight-reduction endpoint versus placebo in all four active dose regimens (P < 0.001).
• Efficacy estimand placebo-adjusted weight loss reached 10% (Arm 1) and 12.3% (Arm 3) at week 28; treatment-policy estimands were 8.4% and 10.5%.
• Patients dosed weekly through week 12, then monthly to week 28; Pfizer reported no weight-loss plateau at week 28.
• Pfizer plans 10 Phase 3 berobenatide trials in 2026, including weekly VESPER-4/5 and monthly VESPER-6.

What did Pfizer report from VESPER-3?

In a February 3, 2026 Pfizer press release, the company said Phase 2b VESPER-3 investigated monthly maintenance dosing of PF’3944 in adults with obesity or overweight without type 2 diabetes.

Design highlights from that release:

• Ongoing 64-week, randomized, double-blind, placebo-controlled study
• Five arms (~n=54 per arm): four titration-to-monthly regimens plus placebo
• Weekly dosing to week 12, then monthly dosing to week 28 for the topline cut
• Primary endpoint: weight reduction from randomization to week 28

Pfizer said Arms 1 and 3—the low and medium monthly maintenance regimens planned for Phase 3—delivered 10% and 12.3% placebo-adjusted weight loss at week 28 on the efficacy estimand. Detailed results were slated for the American Diabetes Association 86th Scientific Sessions on June 6, 2026.

How was tolerability described?

Pfizer characterized the safety profile through week 28 as consistent with the GLP-1 receptor agonist class. Gastrointestinal treatment-emergent adverse events were predominantly mild or moderate. The company reported no more than one instance of severe nausea or vomiting in any dose group and no instances of severe diarrhea.

Across Arms 1 and 3, five participants discontinued for adverse events in the weekly phase and five in the monthly phase, versus zero placebo discontinuations for adverse events, according to the same release.

How does the June 2026 ADA package expand the story?

A later Pfizer release on berobenatide Phase 2b packages used the berobenatide name and framed multiple VESPER-1/2/3 readouts as support for low, medium, and high Phase 3 dosing, including a potential first monthly GLP-1 RA peptide.

That update also described a VESPER-1 Part B exploratory extension: non-placebo-adjusted weight loss of 15.9% with no plateau at 32 weeks on berobenatide in participants escalated to 2.4 mg weekly (week 60 of the overall study). Teams should keep VESPER-1 extension figures separate from the VESPER-3 monthly primary analysis.

What is next in Pfizer’s obesity Phase 3 plan?

Pfizer said it expects to advance more than 20 obesity-related trials in 2026, including 10 Phase 3 studies of PF’3944. Named pillars include:

• VESPER-4: once-weekly PF’3944 without type 2 diabetes (pivotal; initiated)
• VESPER-5: once-weekly PF’3944 with type 2 diabetes (planned/ongoing per later update)
• VESPER-6: once-monthly PF’3944 in obesity or overweight
• At least seven additional Phase 3 studies aimed at comorbidities and access

PF’3944 is also being studied in combinations, including an amylin analog (PF’3945 / MET-233i) and a GIPR agonist (MET-034i), per Pfizer’s pipeline description.

Why does monthly dosing matter commercially?

Weekly injectables dominate the branded obesity market. A peptide that can step down to monthly maintenance after titration could reduce injection burden if Phase 3 confirms the Phase 2b pattern. Pfizer’s own materials still describe berobenatide as investigational; no FDA approval claim is appropriate yet.

For BD and competitive-intelligence teams, the actionable benchmark is the week-28 placebo-adjusted range (10%–12.3% efficacy estimand; 8.4%–10.5% treatment policy) plus the planned monthly Phase 3 VESPER-6 start—not secondary media paraphrases.

What remains unproven?

VESPER-3 continues to week 64; week-28 data do not prove durability or superiority versus approved weekly GLP-1 or dual agonists. Treatment-policy estimands were lower than efficacy estimands, underscoring adherence sensitivity. Combination regimens and comorbidity Phase 3 studies have not yet reported pivotal efficacy.

Related NovaPharma coverage

• GLP-1 Agonists for Weight Loss: 2026 class overview
• Weight Loss Medications in 2026: GLP-1 Market Shift
• Medicare GLP-1 coverage 2026: Bridge program

Frequently Asked Questions

Primary Sources

1. Pfizer: VESPER-3 monthly dosing Phase 2b topline (Feb 3, 2026)
2. Pfizer: Berobenatide Phase 2b package supporting monthly dosing
3. WHO fact sheet: Obesity and overweight
4. PR Newswire: ADA 2026 berobenatide symposium coverage